LCM
KLRS

Laurion Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Laurion Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,087
Closed -$585K – 997
2021
Q1 		$585K Hold
1,087
– – ﹤0.01% 568
2020
Q4 		$961K Hold
1,087
– – 0.01% 418
2020
Q3 		$688K Buy
+1,087
New +$742K 0.01% 513

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Laurion Capital Management's KLRS Position: Q2 2021 in Review

Laurion Capital Management sold out of Kalaris Therapeutics (KLRS) in Q2 2021, closing a stake of 1,087 shares — an estimated $585K sold.

Laurion Capital Management first reported a position in KLRS in Q3 2020 and held it in 3 quarters. The position peaked at $961K in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2021.

  • Laurion Capital Management reported no remaining Kalaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 1,087 Kalaris Therapeutics shares in Q2 2021, an estimated $585K.
  • Laurion Capital Management first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 3 quarters.
  • Laurion Capital Management's Kalaris Therapeutics position peaked at $961K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.